Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Safety and Efficacy of AM712 in Patients with NAMD [Phase 1]
This update reports Phase 1 safety and preliminary efficacy results for AM712 in patients with Neovascular Age-related Macular Degeneration.
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 4]
This Phase 4 trial evaluated the safety and effectiveness of intravitreal injections of brolucizumab for neovascular age-related macular deg…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration [Phase 3]
Phase 3 study comparing the efficacy and safety of brolucizumab versus aflibercept in Chinese patients with Neovascular Age-Related Macular …
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Targeted Fluorescence Imaging in AMD [Phase 1]
Phase 1 clinical trial update on a targeted fluorescence imaging approach for age-related macular degeneration; the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
Phase 1/2 clinical trial update on KH631 gene therapy for neovascular age-related macular degeneration, focusing on safety and tolerability;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting [Phase 4]
Phase 4 clinical trial investigating artificial intelligence approaches for treating neovascular age-related macular degeneration in real-wo…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
This clinical trial update reports the completion of a study evaluating the real-world effectiveness and safety of brolucizumab in Japanese …
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: A Study of IBI302 in Patients With nAMD [Phase 2]
A Phase 2 clinical trial evaluating IBI302 for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety and efficacy of the RRG001 gene therapy in subjects with neovascular age-related macular de…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration [Phase 3]
A Phase 3 study of brolucizumab in adults with suboptimally anatomically controlled neovascular age-related macular degeneration has complet…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
A UK clinical trial evaluating brolucizumab for neovascular age-related macular degeneration has been terminated, according to the latest up…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment [Phase 4]
A phase 4 trial evaluating aflibercept injected into the eye at customized treatment intervals for neovascular age-related macular degenerat…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) [Phase 3]
Phase 3 study comparing AVT06 with EU-Eylea (ALVOEYE) for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-05Clinical Trial Update: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) [Phase 2]
A Phase 2 pharmacodynamic study of RGX-314 for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration [Phase 1]
A Phase 1 dose-escalation study of IBI333 in neovascular age-related macular degeneration has completed enrollment.
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) [Phase 2]
The Phase 2 ENVISION trial evaluating UBX1325 for neovascular age-related macular degeneration has completed, with safety, tolerability, and…
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: CLN-0046: Treatment of AMD Subjects With OTX-TKI [Phase 1]
Phase 1 clinical trial update for CLN-0046 (OTX-TKI) in neovascular age-related macular degeneration, reporting results from subjects treate…
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This clinical trial update describes the use of DARWEN, an artificial intelligence technology, for eye disorders. It investigates factors in…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: A Study of Longer Interval of IVT IBI302 in Subjects With nAMD [Phase 2]
Phase 2 study evaluating a longer interval between IVT IBI302 injections in neovascular age-related macular degeneration; the trial has comp…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
A completed non-interventional study evaluating whether automated OCT image enrichment with segmentation improves disease activity assessmen…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration [Phase 3]
Phase 3 study evaluating the effects of brolucizumab in adults with neovascular age-related macular degeneration has completed and posted re…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) [Phase 1, Phase 2]
This clinical trial update reports on the safety and bioactivity of AXT107 in subjects with neovascular age-related macular degeneration acr…
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) [Phase 2]
Phase 2 clinical trial update evaluating zoledronic acid as adjuvant therapy for neovascular age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study [Phase 3]
This clinical trial update reports the extension study of brolucizumab for neovascular age-related macular degeneration, evaluating efficacy…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration [Phase 3]
A Phase 3 trial comparing SOK583A1 to Eylea in neovascular age-related macular degeneration has completed with results posted.